Abstract: In one embodiment, a method includes rendering a first output image comprising one or more augmented-reality (AR) objects for displays of an AR rendering device of an AR system associated with a first user. The method further includes accessing sensor signals associated with the first user. The one or more sensor signals may be captured by sensors of the AR system. The method further includes detecting a change in a context of the first user with respect to a real-world environment based on the sensor signals. The method further includes rendering a second output image comprising the AR objects for the displays of the AR rendering device. One or more of the AR objects may be adapted based on the detected change in the context of the first user.

Abstract: Provided herein is a photonic integrated circuit and methods for controlling a photonic integrated circuit that can utilize the resonant frequency of one or more components of the photonic integrated circuit to enhance the response of the circuit. At least one component of the photonic integrated circuit can be driven by an electrical signal whose frequency is substantially equal to the mechanical resonance frequency of the component such that the response of the optical component is increased. The component of the photonic integrated circuit can include a phase shifter that can impart a phase shift on a received optical signal. By driving the phase shifter with an electrical signal that is equal to the mechanical resonance frequency of the optical phase shifter, less power can be required to impart a desired phase shift on a received optical signal. The optical components can be implemented using piezoelectric cantilevers.

Abstract: A ballooning patient interface has a frame that supports a sealing member. The frame and/or the sealing member is secured to the head of a user with headgear, such as a strap. Various features of the sealing member improve comfort for the user in the nares of the users as well as on facial surfaces in contact with the sealing member.

Abstract: The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.

Abstract: The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.

Abstract: The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.

Abstract: The present invention includes compositions and methods for enhancing T cell based immunotherapy. In certain aspects, the invention includes modified T cells and inhibitors of Dhx37 for use in enhancing T cell based immunotherapy and treating cancer.

Abstract: The present invention includes dead-guide RNA (dgRNA) libraries and methods of use in immunology and immunotherapy thereof. Also provided are engineered primary or chimeric antigen receptor (CAR) T cells that overexpress Prodh2, Ccnblip1, Sreklip1, or Wdr37or a fragment thereof, and methods of use in immunology and immunothereapy thereof.